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Abstract 
Many children with autism spectrum disorders (ASDs) 
suffer from gastrointestinal problems such as diarrhoea, 
constipation and abdominal pain. Such symptoms may 
be due to a disruption of the indigenous gut microbiota 
promoting the overgrowth of potentially pathogenic 
microorganisms. These observations have stimulated 
investigations into possible abnormalities of intestinal 
microbiota in autistic patients. The purpose of the present 
study was to determine if a relationship exists between 
ASD severity (mild – severe) and gastrointestinal (GI) 
microbial populations. The faecal microbiota of 22 male 
and 6 female participants with ASDs (aged 2-14  years) 
were analyzed by standard microbial culture methods 
and compared within-group (based on ASD severity) and 
with a standard laboratory reference range. Comparisons 
between children with mild ASD and those with 
moderate to severe ASD, as well as comparisons to a 
neurotypical control group previously reported, revealed 
that no significant differences appear to exist in the 
composition of the gut microbiota. Nevertheless, 
examination of each individual’s gut microbial 
composition showed 10 cases of unusual findings which 
means 1 out of 3 cases have unusual microbiota. Our 
data do not support consistent GI microbial abnormalities 
in ASD children, but the findings do suggest that 
aberrations may be found in a minority of ASD children. 
Further studies are required to determine the possible 
association between the microbiota and gastrointestinal 
dysfunctions in a subset of children with both ASD and 
gastrointestinal problems. 
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Introduction 
Autism spectrum disorders (ASD) are behaviorally 
defined developmental disorders (including autistic and 
Asperger’s disorder) with a wide range of behaviours. 
Although the etiology of ASD is unknown, data suggest 
that autism may have multiple etiologies with both 
genetic and environmental contributions (Herbert, 
2010). This diverse etiology may explain the spectrum 
of observed behaviours seen in affected individuals. 
Nevertheless, recent studies have suggested 
gastrointestinal (GI) disorders and associated symptoms 
are commonly reported in individuals with ASD, but 
key issues such as the prevalence and best treatment of 
these conditions are incompletely understood (Buie, 
Campbell et al., 2010; Buie, Fuchs et al., 2010; 
Galiatsatos, Gologan, & Lamoureux, 2009; Gondalia, 
Palombo, Knowles, & Austin, 2010). The clinical 
picture of GI disturbance includes constipation, 
diarrhoea, foul-smelling stools, gaseousness, abdominal 
bloating, signs of abdominal discomfort, and decreased 
intestinal carbohydrate digestive enzyme activity 
(Horvath, Papadimitriou, Rabsztyn, Drachenberg, & 
Tildon, 1999). Nevertheless, the incidence and nature of 
GI symptoms in those with ASD remains somewhat 
uncertain and, even, controversial (Ibrahim, Voigt, 
Katusic, Weaver, & Barbaresi, 2009; Kuddo & Nelson, 
2003; Molloy & Manning-Courtney, 2003). 
Reasons to consider that microorganisms may be 
involved in autism include the following; 
gastrointestinal symptoms are common at ASD onset 
and often persist, antimicrobials (e.g., oral vancomycin) 
may lead to a clear-cut response and relapse may occur 
when the vancomycin is discontinued, and some 
patients have responded to several courses of 
vancomycin and relapsed each time it was discontinued. 
Vancomycin has proven effective in reducing autistic 
symptomatology and is known to be highly effective 
against Gram-positive organisms. When given orally, 
vancomycin is poorly absorbed by the gut, so any effect 
seen with its use is likely due to its action on intestinal 
bacteria (Finegold, 2008; Sandler et al., 2000). 
One hypothesis is that the toxins produced by 
microorganisms may play an important role in the cause 
of ASD, in particular, lipopolysaccharides (LPS), the 
bacterial toxins from Gram-negative bacteria (Gondalia 
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et al., 2010). LPS induces a depressive syndrome, 
characterized by anhedonia, anorexia, body weight loss, 
and reduced locomotor, exploratory, and social 
behaviours (Marvel, Chen, Badr, Gaykema, & Goehler, 
2004; Singal, Tirkey, Pilkhwal, & Chopra, 2006). LPS 
toxicity works synergistically with mercury and other 
heavy metal poisonings to expand damage (Rumbeiha, 
Fitzgerald, Braselton, Roth, & Kaneene, 2000). 
Interestingly, mercury is arguably a suspect as an 
environmental trigger in some etiological theories of 
ASD (Austin, 2008; Bernard, Enayati, Redwood, 
Roger, & Binstock, 2001; Palmer, Blanchard, Stein, 
Mandell, & Miller, 2006; Palmer, Blanchard, & Wood, 
2009). 
The microbiological ecosystem of the gut is complex 
and not completely understood, but appears to be of key 
importance in health and disease (Gibson & Roberfroid, 
1995) and is often conceptualized as an essential 
"organ"
 
in providing nourishment, regulating epithelial 
development,
 
instructing innate immunity and a broad 
range of other activities. Intestinal bacteria secrete both 
detrimental and beneficial compounds and overgrowth 
of certain species of bacteria or other changes to the 
normal intestinal microbiota have been reported with 
ASD (Finegold et al., 2002; Yap et al., 2010). The 
treatment of GI dysfunction in ASD with anti- or 
probiotics has been proposed as a way to regulate 
intestinal microbiota and subsequently improve 
symptom severity in ASD (Sandler et al., 2000; Tuohy, 
Probert, Smejkal, & Gibson, 2003). The variable results 
reported are not surprising given the lack of consistent 
evidence as to the specific microbial adjustment that is 
desirable. While many studies have compared the faecal 
microbiota of individuals with ASD to controls 
(Finegold et al., 2002; Parracho, Bingham, Gibson, & 
McCartney, 2005; Song, Liu, & Finegold, 2004), only 
one has examined the relationship between faecal 
microbiology and ASD severity (Finegold et al., 2010). 
The purpose of the present study was, therefore, to 
determine if a relationship exists between ASD severity 
(mild – severe) and GI microbial populations. Such an 
association would be consistent with a dose-response 
relationship whereby GI microflora aberrations are 
considered to play a role in the aetiology of the disorder 
or, alternatively at least, a mechanistic role related to 
symptom severity. 
Method 
Participants 
Twenty-eight individuals aged 2-14 years (M = 4.8, 
SD = 3.3; 22 male and 6 female) with ASD participated 
in this study. None of the participants were taking 
antibiotics within 14 days prior to the sampling. Dietary 
intake was not controlled and so this likely varied 
across individuals. The participants were recruited from 
consecutive patients presenting to the private 
psychology practice of the fourth author. The study was 
approved by the Human Research Ethics Committee of 
Swinburne University of Technology, and informed 
consent was given by parents on behalf of their children 
who participated in the study.  
Faecal sampling and analysis 
Faecal microbial analysis by standard microbial 
culture methods was carried out by a commercial 
laboratory, Bioscreen Medical 
(www.bioscreenmedical.com). Participants were 
provided with a sample collection kit containing a 
specimen container (lid with two holes), an air-locked 
plastic bag, two gel freezer packs and an AnaeroGen 
Compact foil sachet (Oxoid, UK) to create anaerobic 
conditions inside the plastic bag. 
Faecal samples were collected in specimen containers 
with a scoop attached to the lid. Participants were 
instructed to collect enough faeces to fill at least 1/3 of 
the scoop with faeces from used toilet paper. 
Participants were instructed to screw the lid on firmly, 
place the container in the plastic bag along with an 
opened AnaeroGen Compact foil sachet and seal the 
bag to make it airtight. For transport to the laboratory, 
samples were sealed in a polystyrene box together with 
two freezer packs. 
Statistical methods 
Faecal microbial analysis was carried out to identify 
the presence and quantities of bacteria (aerobes and 
anaerobes), and the yeast, Candida. Analysis of 
variance was used to examine difference between mild 
and severe ASD groups. Data analysis was also carried 
out between the ASD groups as a whole and the 
commercial laboratory reference ranges. Various 
groups of organisms were also analysed for possible 
significant associations and data from this study were 
compared with that from published control group data 
(Finegold, Flora, Attebery, & Sutter, 1975) as well as to 
the laboratory reference ranges. Data were analyzed 
using the Statistical Package for Social Sciences 
(SPSS). 
Results & Discussion 
Participants were divided into two groups: those with 
moderate to severe ASD (n = 16) and those with mild 
ASD (n = 12) (Table 1). The severity category was 
based on CARS (Childhood Autism Rating Scale) 
assessments conducted by registered psychiatrists or 
psychologists and the child’s score reported by parents’ 
of participants. Scores of less than 37 are considered 
mild and those at or above 37 are considered moderate 
– severe (Rellini, Tortolani, Trillo, Carbone, & 
Montecchi, 2004). Details on the specific bacteria 
recovered with ranges and converted mean counts are 
given in Table 2. These counts represent a conversion 
from the means obtained after log transformation of the 
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data values. The log transformation was used because 
of extremely skewed distributions of some organisms, 
which reflected relatively small sample numbers. All 
counts are based on weight of dry stool.  
Analyses of variance revealed no significant 
differences between the two ASD severity groups on 
mean levels for any of the analytes (see Table 1). 
Furthermore, no relationships were evident between the 
levels of any bacterial populations examined across age 
and gender. Inspection of each individual case revealed 
some aberrant results, but not in a consistent or 
common enough pattern to significantly affect the mean 
group levels. Ten ASD children appeared to show more 
variation in microbial profile than the other 18 ASD 
children (see Table 3). Given the lack of associations 
between GI microflora population levels and autism 
severity we decided to compare our total sample means 
with the normal laboratory reference ranges as well as 
means reported for neurotypical individuals in a 
previously published study (Finegold et al., 1975).  
 
 
Table 1 
Mean values of faecal microbiota examined for 
different groups (mild vs. moderate-severe) of ASD 
individuals 
 Mild 
ASD 
group 
(n = 12) 
Moderate to 
severe ASD 
group 
(n = 16) 
P-value 
Total bacterial count 10.26 10.36 .62 
Total aerobe count 7.31 7.37 .83 
Total anaerobe count 10.26 10.35 .64 
Candida 2.48 3.98 .07 
Escherichia coli 6.44 6.69 .55 
Enterococcus spp. 6.79 6.51 .58 
Staphylococcus spp. 5.62 5.63 .98 
Streptococcus spp. 6.71 6.73 .96 
Bifidobacterium spp. 9.14 9.38 .52 
Clostridium spp. 7.24 7.47 .79 
 
 
Anecdotal reports by parents and several recent 
reports have provided evidence that ASD children 
suffer from disturbed GI tract function (Buie, Campbell 
et al., 2010; Buie, Fuchs et al., 2010). Nevertheless, 
comprehensive assessments of GI abnormalities in ASD 
children are not widely or routinely performed. In the 
present study, comparisons between children with mild 
ASD and those with moderate to severe ASD (Table 1), 
as well as comparisons to a neurotypical control group 
(Table 2), revealed that significant differences did not 
appear to exist in the composition of the gut microbiota. 
However, examination of each individual’s gut 
microbial composition showed occasional cases of 
unusual findings. For example, in four ASD 
participants, we found low numbers of total bacterial 
and total aerobes (patients 1, 2, 7 and 9). Escherichia 
coli levels were lower than the normal range in ASD 
patients 2, 4 and 5, while other aerobic bacteria 
(Citrobacter spp., Enterobacter spp., Staphylococcus 
and Streptococcus spp.) were higher than the normal 
range in two ASD patients and Bifidobacterum were 
significantly higher than the normal range. Clostridium 
spp was higher in patient 8 (see Table 3).  
There are several important limitations to this study 
that should be acknowledged. One is the small sample 
size, and the resultant limitations to generalisability of 
the findings and statistical power. Also, we did not 
utilise a control group but, rather, compared our clinical 
data to previously published data and laboratory 
reference ranges for normal control populations. A 
further limitation was our single time-point sampling 
which does not allow for determining stability of 
microbial populations over time. Finally, we did not 
control for dietary differences amongst our participants. 
Obviously, it would be ideal to experimentally 
manipulate dietary intake to remove its influence on GI 
microbiology. 
The kind of individual aberrations found in our 
sample are consistent with the current consensus that GI 
dysfunction does occur more frequently in ASD than 
non-ASD children (Buie, Campbell et al., 2010), but 
possibly only in a minority of individuals It is critical, 
therefore, for future research to attempt to identify this 
minority a priori in order to conduct more advanced 
testing beyond group mean comparisons which our 
study show may dilute (at a group level) any aberrations 
apparent in the minority of children. Furthermore, 
future researchers should cast a wider net in their search 
for microbial correlates in ASD. All studies conducted 
to date have examined only a fraction of the microbial 
species known to inhabit the gut, both pathogenic and 
commensal. Additionally, microbial species beyond 
bacteria should be examined, including viruses, fungi 
and protozoa. If microbial correlates to the GI 
dysfunction seen in ASD can be identified, promising 
opportunities for influencing the clinical course of the 
GI disturbance through appropriate intervention may be 
developed, such as pro- or antibiotic therapy or dietary 
intervention.  
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Table 2 
Comparison of bacterial counts between individuals with an ASD, control group and laboratory reference range 
 Lab ref 
(n = 177)a 
 Total ASD 
(n = 28) 
  Controlb 
(n = 25) 
 
 Range n Rangec Converted 
mean 
n Rangev Converted 
mean 
Total bacterial count        
Total bacterial count 11-12 28 9-12 10.32 25 - 10.55 
Total aerobe count 7-8 28 5-9 7.35 25 - 9.92 
Total anaerobe count 8-12 28 9-12 10.31 25 - 11.58 
Candida < 4 18 0-6 3.49 - - 3.39 
        
Facultative Gram negative bacteria       
Escherichia coli 7-8 27 4-8 6.59 23 4-11 8.10 
Klebsiella spp. <5 3 4-7 5.48 12 4-10 4.81 
Citrobacter spp. <6 0 - - 1 8 2.76 
Enterobacter spp. <6 4 5-7 6.24 1 4 2.17 
        
Facultative Gram positive bacteria       
Enterococcus spp. <6 9 6-7 6.41 - - - 
Staphylococcus spp. <5 8 5-7 5.63 9 4-10 4.44 
Streptococcus spp. <6 25 5-9 6.73 - - - 
Alpha-haemolytic Streptococcus <6 14 4-8 6.66 9 5-11 3.91 
Beta-haemolytic Streptococcus <6 5 4-6 5.17 - - - 
Non-haemolytic Streptococcus <6 22 4-9 6.43 - - - 
        
Anaerobic Gram negative bacteria       
Bacteroides 8-12 27 9-11 9.93 10 - 9.63 
Prevotella spp <10 19 9-11 9.73 - - - 
Porphyromonas spp. <9 2 9-10 9.80 - - - 
Eurobacterium <9 7 9-11 9.67 - - - 
        
Anaerobic Gram positive bacteria       
Eubacterium <9 0 - - - - - 
Bifidobacterium spp. 7-9 22 7-10 9.29 10 - 8.31 
Lactobacillus spp 6-8 8 7-10 8.24 10 - 6.90 
Clostridium spp. <9 28 0-10 9.71 - - - 
Peptostreptococcus spp. <5 1 0-10 9.71 - - 5.91 
Note: aBioscreen (2009); bFinegold et al (1975); cLog10 no. of organisms per g of faeces (rounded off to nearest log in the case of range) 
 
 
 
Gondalia, Palombo, Knowles & Austin: Faecal microbiota of individuals with an ASD           28 
Electronic Journal of Applied Psychology. 6(2):24-29 (2010) 
Table 3 
Microbiological data from examination of faecal samples obtained from 10 selected children with abnormal microbiota 
compared with a control group 
 Microbiological data, by patient number 
Organism isolated Control 
group 
converted 
meana,b 
Patient 
1 
Patient 
2 
Patient 
3 
Patient 
4 
Patient 
5 
Patient 
6 
Patient 
7 
Patient 
8 
Patient 
9 
Patient 
10 
Total bacterial count 10.55 9.61 8.98 10.28 10.51 10.26 10.28 9.91 11.18 9.36 10.43 
Total aerobe count 9.92 8.84 5.00 7.18 7.43 5.96 8.57 6.73 6.58 6.18 8.20 
Total anaerobe count 11.58 9.58 8.98 10.28 10.51 10.26 10.28 9.91 11.18 9.36 10.43 
Candida 3.39 6.08 . . . . . . 4.85 . 4.46 
Escherichia coli 8.10 6.94 4.08 7.18 5.90 4.87 6.97 6.61 6.08 6.11 . 
Klebsiella spp. 4.81 . . - 6.51 4.20 . . . . . 
Enterococcus spp. - 7.11 . - . . . . 5.36 . . 
Staphylococcus spp. 4.44 6.48 . - 5.20 . 5.57 . . . 4.88 
Streptococcus spp. - 8.82 4.49 4.79 7.36 5.91 8.56 6.15 . 5.32 8.20 
Bifidobacterium spp. 8.31 8.83 7.32 . 8.75 9.20 . 9.43 . 7.92 . 
Lactobacillus spp. 6.90 7.83 . . - - 9.67 - - . 8.94 
Clostridium spp - 4.61 6.79 9.96 9.90 4.61 5.82 9.15 10.23 6.49 9.83 
Note: aFinegold et al (1975); bLog10 no. of organisms per g of faeces (rounded off to nearest log in the case of range) 
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